AMNOG 2.0: How Germany is debating the future of benefit assessment
AMNOG 2.0 is the emerging debate about how Germany should balance early access to innovative medicines, robust evidence requirements and the financial sustainability of its statutory health insurance system. Some innovative medicines enter the market with greater evidence uncertainty, additional evidence may only become available after launch, while healthcare expenditure continues to rise.
The debate also matters beyond Germany. The EU Health Technology Assessment (HTA) Regulation has introduced Joint Clinical Assessments (JCAs), creating a common European clinical assessment that feeds into national HTA processes. JCAs have applied to new oncology medicines and advanced therapy medicinal products (ATMPs) since January 2025; orphan medicines will follow in 2028 and all new centrally authorised medicines in 2030. Germany is therefore discussing the future of AMNOG while the European evidence environment is changing. AMNOG 2.0 is not an enacted reform package at this stage, but an ongoing policy debate.
A specific feature of the German system shapes this debate: early benefit assessment does not generally determine whether a newly authorised medicine is available to patients. Newly authorised medicines are generally reimbursable from market entry. The reform question therefore concerns less access itself than how added benefit should be assessed under uncertainty and how that assessment should subsequently translate into the reimbursement amount.
Four questions define the AMNOG 2.0 debate
- How early should patients gain access to innovative medicines?
- How much evidence should be required at market entry to establish added benefit?
- How should additional evidence generated after launch feed back into benefit assessment?
- How can early access to innovation remain financially sustainable?
Orphan medicines, ATMPs and targeted therapies can involve small populations, limited comparative evidence or uncertainty about long-term outcomes at launch. Industry proposals therefore call for greater flexibility in specific treatment situations and use of the best available evidence. At the same time, statutory health insurance expenditure remains under pressure. The resulting policy question is how uncertainty should be managed when early access, evidence requirements and financing pull in different directions.
How much evidence should AMNOG require at market entry?
The first major reform question concerns the evidence threshold for medicines addressing significant medical need when their evidence base remains uncertain at launch. According to the GKV-Spitzenverband, the BMG has discussed special treatment for medicines with regulatory designations including PRIME, Accelerated Assessment, Conditional Marketing Authorisation and authorisation under exceptional circumstances. Under the approach described by the GKV-Spitzenverband, a positive quantified added benefit could be recognised despite greater uncertainty in the underlying evidence.
The problem is particularly visible in small populations and severe diseases. Conventional comparative evidence can be difficult to generate before launch, and long-term outcomes may not yet be observable. Reform proposals therefore include formal recognition of specific treatment situations and greater consideration of the best evidence that can reasonably be generated. The G-BA also identifies a potential incentive problem. A special pathway could result in a medicine with limited evidence and a specific regulatory status being assessed under different standards from a medicine with more robust evidence and regular marketing authorisation. The GKV-Spitzenverband similarly emphasises that early benefit assessment serves a different purpose from marketing authorisation and should make evidence uncertainty transparent. The counterargument is that marketing authorisation and German early benefit assessment answer different questions: authorisation concerns the benefit-risk balance, while AMNOG asks whether patient-relevant added benefit is demonstrated against the comparator relevant to German care.
What could change?
A lower or more flexible initial evidence threshold would make management of residual uncertainty after launch more important. The evidence pathway could increasingly look like this: marketing authorisation → initial benefit assessment → additional evidence generation → reassessment. The key question would be which remaining uncertainties can realistically be resolved afterwards.
How should post-launch evidence feed into AMNOG reassessment?
According to the GKV-Spitzenverband’s description of the BMG proposals, regular reassessments are being considered for certain medicines. Data from Germany’s Health Research Data Centre (Forschungsdatenzentrum Gesundheit, FDZ) could potentially contribute in the future. Longer follow-up, new clinical data cuts and suitable real-world data could become part of a subsequent assessment cycle. The discussion about reassessment leads directly to the question of data fitness. The G-BA considers the current FDZ dataset problematic for this type of benefit assessment. Diagnosis and claims data do not automatically capture clinical endpoints, disease stage or other characteristics required for a specific benefit assessment. In rare diseases, sufficiently granular diagnosis codes may also be unavailable. This leads to an important principle for real-world evidence in AMNOG: the availability of a dataset should not determine the assessment question. The decisive issue is whether the data are fit for the specific evidence question.
The central disagreement concerns when reassessment is justified. The GKV-Spitzenverband argues that it should primarily take place when the evidence base has materially changed and a meaningful gain in knowledge can be expected. A more systematic model would require manufacturers to anticipate which evidence could become available two, three or more years after launch and which initial uncertainties it could address. The role of German registries, claims data and FDZ data is covered separately in our analysis of Real-World Evidence in the AMNOG dossier.
How could AMNOG recognise medical need without replacing evidence-based benefit assessment?
The G-BA introduces an alternative approach into the AMNOG 2.0 debate. The regular data-based benefit assessment by the Federal Joint Committee (G-BA) and the Institute for Quality and Efficiency in Health Care (IQWiG) would remain in place for all new medicines. For specific treatment situations, an additional assessment could determine whether there is a “potential for a therapeutically relevant added benefit”.
Under the proposal, such a finding could be considered when the regular evidence does not establish added benefit but there are indications of a meaningful improvement in therapy compared with the appropriate comparator therapy (zweckmäßige Vergleichstherapie, zVT). The supplementary qualitative assessment could consider alternative endpoints, indirect comparisons with greater uncertainty and clinical input from medical experts.
The potential pathway would therefore not automatically translate greater evidence uncertainty into a regular quantified added benefit. Instead, it could introduce an intermediate step:
No data-based added benefit → potential for a therapeutically relevant added benefit → additional evidence → reassessment
For the subsequent reassessment, the G-BA proposes that the evidence base should not be restricted to FDZ data. The pharmaceutical company should be able to determine which data are submitted for reassessment.
This creates a second reform model alongside a more flexible initial evidence threshold: Should AMNOG accept greater uncertainty within the existing added-benefit assessment, or should therapeutic potential be recognised separately until more robust evidence becomes available?
Which endpoints and evidence standards should apply to AMNOG?
The third reform question concerns how closely German benefit assessment should connect to evidence generated for regulatory approval. According to the GKV-Spitzenverband, the proposals discussed by the BMG would allow endpoints used in the regulatory process to be treated initially as “provisionally patient-relevant” for certain medicines. An endpoint may support a regulatory decision without necessarily meeting German requirements for demonstrating patient-relevant added benefit.
Industry proposals seek greater recognition of endpoints accepted at European level and key endpoints from pivotal regulatory trials. Other proposals call for more flexibility regarding surrogate endpoints and alternative evidence in specific treatment situations. Greater acceptance of regulatory endpoints could make European and regulatory evidence easier to use within German benefit assessment, while making the subsequent management of uncertainty more important.
How predictable should the German comparator be?
The appropriate comparator therapy (zweckmäßige Vergleichstherapie, zVT) is central to AMNOG because it defines the treatment against which added benefit is assessed. The GKV-Spitzenverband calls for an earlier and more binding determination of the zVT. The vfa similarly calls for greater predictability where clinical trials have been designed in accordance with prior advice from Germany’s Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA).
Clinical evidence generation starts years before an AMNOG dossier is submitted. If the German comparator changes after a pivotal trial has been designed or completed, the evidence may become less directly applicable. A more predictable comparator would improve long-term evidence planning, especially as European PICO scoping, JCA requirements and German comparator requirements increasingly need to be considered within one development programme.
How should AMNOG connect with EU HTA?
Under the EU HTA Regulation, JCAs provide a scientific analysis of the relative clinical effects of a health technology. They support national HTA processes rather than replacing national decisions on added value, reimbursement or pricing. The first JCA report for a medicine was published in June 2026, turning the European framework into an operational assessment process. Germany’s Pharmaceutical and Medical Technology Dialogue places benefit assessment and EU HTA within the same working group.
The vfa calls for greater use of European assessment results within AMNOG, closer alignment of analytical requirements, greater consideration of European endpoints and better timing between JCA and the national process. For manufacturers, early alignment of PICO, endpoints, comparator strategy and evidence generation will become even more important. The German concept of the delta dossier describes the additional national evidence and analyses required to translate the European JCA evidence package into a dossier that meets German AMNOG requirements; it is not an official regulatory designation.
Why are orphan medicines and ATMPs central to the debate?
Orphan medicines and ATMPs concentrate many of the tensions behind AMNOG 2.0. Small patient populations, limited comparative evidence, potentially long-lasting treatment effects and difficult trial conditions can make conventional evidence generation challenging. ATMPs have been subject to mandatory JCA since January 2025, while orphan medicinal products will enter the scope in January 2028.
Regulatory status and medical need should not automatically be treated as equivalent. The G-BA notes that orphan designation may also be based on an expected “significant benefit” compared with existing treatment options. Orphan designation therefore does not automatically identify a treatment situation in which no satisfactory alternatives are available. This creates an important design question for AMNOG 2.0: Should eligibility for a special assessment pathway depend primarily on regulatory status, or should it be linked more directly to the actual treatment situation and unmet medical need?
How can early access and financial sustainability be reconciled?
Behind the methodological debate lies a broader trade-off between rapid access to innovation and the financial sustainability of Germany’s statutory health insurance system. The BMG describes rapid availability of new medicines as an existing strength, while its Pharmaceutical and Medical Technology Dialogue aims to strengthen innovation and security of supply while containing increases in healthcare costs. In the first half of 2026, expenditure growth across statutory health insurance remained above the growth of contribution-based revenues. In the first half of 2026, expenditure growth across statutory health insurance remained above the growth of contribution-based revenues. The potential scope of a special pathway is also part of the debate. According to the G-BA’s analysis, the regulatory criteria under discussion would capture more than 60% of assessments involving new active substances. For 2025, the G-BA reports a range of 71.1% to 89.5%, depending on which regulatory criteria are included. These are calculations presented by the G-BA and depend on the criteria included. This raises a system-level question: Can an assessment pathway still function as an exception for specific treatment situations if it potentially applies to a large proportion of newly assessed medicines?
The fundamental question is how much evidence uncertainty a solidarity-based healthcare system should accept in exchange for earlier access to innovative medicines, and how that uncertainty should later be reflected in evidence generation, reassessment and reimbursement.
What AMNOG 2.0 could mean for evidence planning and market access
- Evidence planning could extend further beyond launch if reassessment becomes more systematic.
- Regulatory and HTA evidence could become more closely connected, increasing the importance of coordination between Regulatory Affairs, Clinical Development, HEOR and Market Access.
- European and German evidence strategies could converge further through the sequence: clinical development and PICO planning → JCA → AMNOG → additional evidence generation → potential reassessment.
What central question remains open for AMNOG 2.0?
The new G-BA statement adds another possible approach. Evidence uncertainty does not necessarily have to be addressed by recognising regular added benefit under more flexible evidence requirements. An alternative model could distinguish between data-based added benefit and an initially recognised therapeutic potential. This makes the central question for AMNOG 2.0 more specific: Should greater evidence uncertainty be accepted within the added-benefit assessment itself, or does AMNOG need a separate category for therapeutic potential until more robust evidence becomes available? Both approaches would make additional post-launch evidence more important. However, they differ in how uncertainty is represented in the initial benefit assessment and, consequently, how it could feed into subsequent reimbursement. For manufacturers, the relevant question is therefore not only whether reassessments will become more common. It is also which evidence will be sufficient to establish added benefit at market entry and which evidence may later be required to confirm therapeutic potential or an initially uncertain added benefit.